The present study was designed to identify the histopathological effect of fluoxetine (fluoxetine hydrochloride) on the pregnant mice brain and their fetuses as well as recording weight changes at doses of 60 and 80 mg/kg of body weight which were administrated to the pregnant mice from the 7 th up to the 18 th day of pregnancy and once a day. The results showed histopathological lesions in the adult pregnant mice brain at the dose of 60 mg/kg. induced massive necrotic area of neurons in the cerebral cortex, necrosis of the molecular layer cells while the dose of 80 mg/kg the changes include vasogenic edema in the sub cortical area, severe degeneration and necrosis of the cortex. The lesions in cerebellum were more severe than recorded in the cerebrum. The results also showed the presence of many lesions in the fetus brain at the dose 60 mg/kg and they were degeneration, necrosis of many neurons in the cerebrum while at the dose of 80 mg/kg. There were increase of degeneration and necrosis in the cortical area of fetus brain. In conclusion, the use of fluoxetine in pregnant mice caused decrease in body weight and Histopathological changes in the brain of both of the mothers and their embryos, thus the use of antidepressant by pregnant woman can be harmful for the mothers and the fetus.

The current study was done to investigate the effects of two doses 3and 6 mg/kg B.w. of the Platinum drug on the structure of the liver and kidney of pregnant mice, and embryos in addition to the weight of the mothers, embryos, maternal liver and kidneys, as well as some biochemical parameters, were established. For this study, thirty pregnant mice were used, divided into three groups (10 mice/group) as follows; group I (control group); animals were injected intraperitoneally (IP) with distilled water on the days 7th, 12th, and 17th of gestation. The other both groups II, and III were injected intraperitoneally (IP) with the selected doses above of the Platinum at the days 7th, 12th, and 17th of gestation, respectively. Microscopically, maternal and fetal' liver sections of group II revealed vacuolation, swelling, apoptosis, infiltration of inflammatory cells, congestion, degeneration, and presence of the extramedullary hematopoietic cells, respectively. Previous lesions were increased in group III. Maternal and, fetal kidney sections of group II revealed degeneration, expansion of Bowman's space, inflammatory cells infiltration into interstitial tissue, and blood capillaries congestion. However, the previous lesions showed more severity in group III. The drug caused a reduction in the body weight of the mothers, selected organs, and embryos. Biochemical assessment of the maternal serum AST, ALT, and ALP levels showed an increase in both experimental groups II and III, but to varying degrees. Moreover, both groups II and III showed an increase in the levels of the maternal BUN and, urea. Whist, group III showed a significant increase of the creatinine compared to the control group. In conclusion, using anticancer drugs during pregnancy will harm both mothers and fetal organs. The risk of these medications represents their ability to cross the placenta and enters the fetal body. Therefore, the drug may affect the formation of the fetal organs. The drug also alters the regulatory antioxidant mechanism in the maternal body during the treatment duration. The drug should be used under medical follow up.